UCB S.A. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2016', provides an overview of the UCB S.A.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A. - The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses UCB S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features UCB S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for UCB S.A. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding UCB S.A.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 UCB S.A. Snapshot 6 UCB S.A. Overview 6 Key Information 6 Key Facts 6 UCB S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 UCB S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 UCB S.A. - Pipeline Products Glance 16 UCB S.A. - Late Stage Pipeline Products 16 Pre-Registration Products/Combination Treatment Modalities 16 Phase III Products/Combination Treatment Modalities 17 UCB S.A. - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 UCB S.A. - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Discovery Products/Combination Treatment Modalities 21 UCB S.A. - Drug Profiles 22 brivaracetam 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 certolizumab pegol 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 lacosamide 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 levetiracetam 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 rotigotine ER 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 bimekizumab 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 seletalisib 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 UCB-0942 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 UCB-7665 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 dapirolizumab pegol 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 UCB-4144 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 UCB-6673 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Antibodies for Cancer, Immunology and Inflammation 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Antibody to Inhibit Transglutaminase 2 for Fibrosis 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 UCB S.A. - Pipeline Analysis 59 UCB S.A. - Pipeline Products by Target 59 UCB S.A. - Pipeline Products by Route of Administration 61 UCB S.A. - Pipeline Products by Molecule Type 62 UCB S.A. - Pipeline Products by Mechanism of Action 63 UCB S.A. - Recent Pipeline Updates 65 UCB S.A. - Dormant Projects 81 UCB S.A. - Discontinued Pipeline Products 82 Discontinued Pipeline Product Profiles 82 CDP-323 82 CDP-435 82 CDP-484 82 lacosamide 82 seletracetam 83 UCB-2892 83 UCB S.A. - Company Statement 84 UCB S.A. - Locations And Subsidiaries 86 Head Office 86 Other Locations & Subsidiaries 86 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
UCB S.A., Key Information 6 UCB S.A., Key Facts 6 UCB S.A. - Pipeline by Indication, 2016 8 UCB S.A. - Pipeline by Stage of Development, 2016 10 UCB S.A. - Monotherapy Products in Pipeline, 2016 11 UCB S.A. - Partnered Products in Pipeline, 2016 12 UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13 UCB S.A. - Out-Licensed Products in Pipeline, 2016 14 UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15 UCB S.A. - Pre-Registration, 2016 16 UCB S.A. - Phase III, 2016 17 UCB S.A. - Phase II, 2016 18 UCB S.A. - Phase I, 2016 19 UCB S.A. - Preclinical, 2016 20 UCB S.A. - Discovery, 2016 21 UCB S.A. - Pipeline by Target, 2016 59 UCB S.A. - Pipeline by Route of Administration, 2016 61 UCB S.A. - Pipeline by Molecule Type, 2016 62 UCB S.A. - Pipeline Products by Mechanism of Action, 2016 64 UCB S.A. - Recent Pipeline Updates, 2016 65 UCB S.A. - Dormant Developmental Projects,2016 81 UCB S.A. - Discontinued Pipeline Products, 2016 82 UCB S.A., Subsidiaries 86
List of Figures
UCB S.A. - Pipeline by Top 10 Indication, 2016 8 UCB S.A. - Pipeline by Stage of Development, 2016 10 UCB S.A. - Monotherapy Products in Pipeline, 2016 11 UCB S.A. - Partnered Products in Pipeline, 2016 12 UCB S.A. - Out-Licensed Products in Pipeline, 2016 14 UCB S.A. - Pipeline by Top 10 Target, 2016 59 UCB S.A. - Pipeline by Route of Administration, 2016 61 UCB S.A. - Pipeline by Molecule Type, 2016 62 UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 63
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption ratRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.